Sites
Q&A Part I with Dr. Wendy Tate, Author of Insights Accrual Prediction Algorithm
This March, Insights Accrual Prediction platform was released to pilot customers. We sat down with Dr. Wendy Tate, the author behind the machine learning tool’s algorithm, to learn what inspired her to tackle this industry hurdle and hear her experience bringing this innovative tool to the research community.
Building Remote Workflows within eRegulatory Document Management: Subject Binders & SOPs
Advarra eRegulatory Management System now supports the storage and remote monitoring of Subject Binders and SOPs, increasing compliance, and centralizing your study documents.
Understanding the Complexity and Uniqueness of Phase I Trials
There are many distinctions that set Phase I trials apart from the rest. For sites aiming for a successful Phase I trial, working with an organization that understands the nuances is key.
mRNA and Its Role in Clinical Research
Messenger RNA (mRNA) has made recent headlines due to its role in Operation Warp Speed. This article explores how its technology is used to fight the COVID-19 pandemic.
Does Warp Speed Vaccine Development and Testing Compromise Safety?
Fiction often shows warp speed travels not going as planned, but what does warp speed mean for vaccine development in clinical research?
Top 10 Educational Resources of 2020
We strive to create meaningful and relevant content for the clinical research community. Check out our top resources of 2020.
New FDA Certificate of Confidentiality Guidance: What Does it Mean for You?
Certificates of Confidentiality protect participant privacy by preventing disclosed sensitive information during research.
Standardization and the Importance of Medical Coding Dictionaries in Clinical Trials
Learn more about the importance of medical coding dictionaries, their common uses, and best practices.
The Many Faces of “Coercion” and “Undue Influence”
Coercion and undue influence in research can be complicated. Understand what these terms mean and how to appropriately protect against them.
Q&A – Racial Diversity in Clinical Trials: Building Trust in Participant Engagement
Our experts answered some of the most popular questions from "Racial Diversity in Clinical Trials: Building Trust in Participant Engagement."
Takeaways From the FDA’s VRBPAC Meeting – October 22, 2020
On October 22, 2020, the FDA's VRBPAC met to discuss the development, authorization, and licensure of vaccines to prevent COVID-19.
Q&A – Study Startup Success for the New Generation of Genetically Engineered Vaccines
Daniel Eisenman answers questions from his latest webinar Study Startup Success for the New Generation of Genetically Engineered Vaccines.